S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:PROC

Procaps Group (PROC) Stock Price, News & Analysis

$2.78
-0.22 (-7.33%)
(As of 03/27/2024 ET)
Today's Range
$2.73
$3.00
50-Day Range
$2.78
$4.34
52-Week Range
$1.95
$5.38
Volume
6,005 shs
Average Volume
28,969 shs
Market Capitalization
N/A
P/E Ratio
5.35
Dividend Yield
N/A
Price Target
$4.50

Procaps Group MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
61.9% Upside
$4.50 Price Target
Short Interest
Healthy
0.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Procaps Group in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
13.33%
From $0.15 to $0.17 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.71 out of 5 stars

PROC stock logo

About Procaps Group Stock (NASDAQ:PROC)

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

PROC Stock Price History

PROC Stock News Headlines

Procaps Group (NASDAQ:PROC) Trading Down 3.4%
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Procaps Issues Shareholder Letter from New CEO
Procaps Group S.A. (PROCW)
PROC Procaps Group S.A.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Procaps Group – Notice to Shareholders
Procaps Group Reports Third Quarter 2023 Results
Procaps Group Names Vieira to Succeed Minski as CEO
Procaps Group Appoints Jose Antonio Vieira To Succeed Ruben Minski As CEO
Procaps Group Update on Third Quarter Results
Procaps Group S.A. Wt
Procaps Group to Participate at CPHI Barcelona 2023
See More Headlines
Receive PROC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Procaps Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/26/2023
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PROC
Fax
N/A
Employees
5,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$4.50
Low Stock Price Target
$4.50
Potential Upside/Downside
+61.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$42.54 million
Pretax Margin
16.36%

Debt

Sales & Book Value

Annual Sales
$409.92 million
Cash Flow
$0.49 per share
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.13
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Ruben Minski (Age 71)
    Founder & Executive Chairman
  • Mr. Jose Antonio Toledo Vieira (Age 57)
    Chief Executive Officer
  • Mr. Patricio Vargas Munoz (Age 51)
    Global Chief Financial Officer
  • Dr. Camilo Camacho (Age 50)
    Chief Operations Officer
  • Ms. Melissa Angelini
    Investor Relations Director
  • Ms. Marcela Carvajalino Pagano (Age 57)
    Vice-President of Corporate & Legal Affairs
  • Mr. Luis Alberto Palacios Aragon (Age 60)
    Vice-President of International Marketing and R&D
  • Mr. Mauricio Castaneda Caballero (Age 47)
    Vice-President of Human Resources
  • Mr. Carlos Piocuda Russo (Age 39)
    Head of Optimization of Corporate Value & Corporate VP of Finance

PROC Stock Analysis - Frequently Asked Questions

Should I buy or sell Procaps Group stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Procaps Group in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PROC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROC, but not buy additional shares or sell existing shares.
View PROC analyst ratings
or view top-rated stocks.

What is Procaps Group's stock price target for 2024?

1 analysts have issued 1 year target prices for Procaps Group's shares. Their PROC share price targets range from $4.50 to $4.50. On average, they anticipate the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 61.9% from the stock's current price.
View analysts price targets for PROC
or view top-rated stocks among Wall Street analysts.

How have PROC shares performed in 2024?

Procaps Group's stock was trading at $4.07 at the beginning of 2024. Since then, PROC stock has decreased by 31.7% and is now trading at $2.78.
View the best growth stocks for 2024 here
.

Are investors shorting Procaps Group?

Procaps Group saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 5,000 shares, a decrease of 51.5% from the February 29th total of 10,300 shares. Based on an average trading volume of 24,900 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company's shares are sold short.
View Procaps Group's Short Interest
.

When is Procaps Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our PROC earnings forecast
.

How were Procaps Group's earnings last quarter?

Procaps Group S.A. (NASDAQ:PROC) posted its earnings results on Tuesday, December, 26th. The company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. The firm earned $118.41 million during the quarter, compared to the consensus estimate of $110.40 million. Procaps Group had a trailing twelve-month return on equity of 283.06% and a net margin of 12.61%.

Who are Procaps Group's major shareholders?

Procaps Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Exome Asset Management LLC (0.11%).

How do I buy shares of Procaps Group?

Shares of PROC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PROC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners